TRADE NEWS: Clone-Based Sequencing, Agilent Technologies’ CGH Microarrays Used to Discover Structural Variation of Eight Human Genomes

SANTA CLARA, Calif.–A group of researchers has provided new insight into processes shaping the human genome. They used a clone-based method to build a comprehensive, fine-scale map of structural variation in eight human genomes from diverse geographic ancestry. Employing a variety of technologies for validation and characterization, including Agilent CGH microarrays, they identified 1,695 sites of structural change, half of which were seen in more than one individual. The work also detected 525 segments of novel sequence not found in the reference human genome sequence.

Custom Agilent CGH microarrays were used to validate structurally variant sequences and to further characterize the novel insertion sequences found by cloning. “We designed array probes based on the novel sequences to measure whether these sequences are copy-number variable among different humans,” said Laurakay Bruhn, Ph.D., a member of the four-person Agilent team that participated in the study. “We found that nearly half of these sequences show copy-number differences between eight individuals, showing they are a rich source of structural variation in the human genome.”

Agilent’s ability to quickly design and fabricate custom microarrays with high sensitivity and specificity for measuring copy-number differences in genomic DNA proved to be an asset for validation and further study of new sequences. Agilent maintains a database of 20 million copy-number variation probes that facilitate experimental design.

The results are published in the May 2008 issue of Nature (vol. 453) in the paper “Mapping and sequencing of structural variation from eight human genomes.” Contributors included researchers from the Howard Hughes Medical Institute and the University of Washington School of Medicine; Agilent Technologies; Agencourt Biosciences Corp.; Washington University Genome Sequencing Center; Human Genome Research Institute, National Institutes of Health; Laboratory of Genetics, University of Wisconsin; Illumina Inc.; and Program in Medical and Population Genetics, Broad Institute of MIT and Harvard.

“The clone resource and the subsequent sequencing and characterization of these genomes will provide a gold standard for future characterization of structural variation,” said Evan Eichler, Ph.D., corresponding author.

The authors wrote that the understanding of genomic variation on an intermediate scale — “particularly insertions, deletions and inversions affecting from a few thousand to a few million base pairs” — provides new insights into the different mutational processes that have shaped the human genome.

About Agilent in Genomics

Agilent is a leading provider of microarray-based, genomics research solutions. Agilent’s end-to-end solutions include reagents hardware for sample QC and high-throughput microarray scanning; 60-mer oligo microarrays on industry-standard 1” x 3” glass slides for gene expression, CGH, methylation, ChIP-on-chip and microRNA profiling. Agilent also provides GeneSpring bioinformatics systems.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A – News) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 19,000 employees serve customers in more than 110 countries. Agilent had net revenues of $5.4 billion in fiscal 2007. Information about Agilent is available on the Web at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news.

< | >